topotecan has been researched along with Colonic Neoplasms in 41 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 15 (36.59) | 18.2507 |
2000's | 13 (31.71) | 29.6817 |
2010's | 12 (29.27) | 24.3611 |
2020's | 1 (2.44) | 2.80 |
Authors | Studies |
---|---|
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL | 1 |
Besterman, JM; Croom, DK; Emerson, DL; Evans, MG; Lackey, K; Leitner, PL; Luzzio, MJ; McIntyre, G; Sternbach, DD; Vuong, A; Yates, J | 1 |
Chen, S; Cheng, J; Dong, G; Fang, K; Huang, Y; Li, Y; Sheng, C; Wang, L; Wu, S | 1 |
Al-Rihani, SB; Ambudkar, SV; Chen, ZS; Kaddoumi, A; Lei, ZN; Shi, Z; Shukla, S; Wang, DS; Wang, YJ; Zhang, GN; Zhang, XY; Zhang, YK | 1 |
Beijnen, JH; Buil, L; Hoogendijk, L; Lin, F; van Tellingen, O | 1 |
Fan, Y; He, H; Qi, X; Wu, Z | 1 |
Gjerset, RA; Zhao, M | 1 |
Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
Animati, F; Bellarosa, D; Bigioni, M; Binaschi, M; Bressan, A; Bugianesi, R; Crea, A; Maggi, CA; Manzini, S; Parlani, M; Rivoltini, L | 1 |
Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z | 1 |
Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
Ashwell, S; Brassil, P; Breed, J; Deng, C; Ezhuthachan, J; Grondine, M; Horn, C; Liu, D; Lyne, P; Newcombe, N; Oza, V; Pass, M; Read, J; Su, M; Toader, D; Yu, D; Yu, Y; Zabludoff, S | 1 |
Fu, LW; Liang, YJ; Su, XD; Wang, F; Wu, XP | 1 |
Francia, G; Hackl, C; Kerbel, RS; Man, S; Milsom, C; Xu, P | 1 |
Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B | 1 |
Chen, SP; Deng, R; Feng, GK; Jiang, S; Li, DD; Pan, JX; Sun, T; Wu, XQ; Zeng, YX; Zhang, XS; Zhu, XF | 1 |
Glomme, S; Hertig, J; Hess, CF; Pradier, O; Rave-Fränk, M; Schmidberger, H; Virsik-Köpp, P; Weiss, E | 1 |
Daoud, SS; Kohn, KW; LaRose, J; Munson, PJ; Pommier, Y; Prabhu, VV; Reinhold, W; Weinstein, JN; Young, L; Yu, Q | 1 |
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
Holcombe, RF; Kong, KM; Wimmer, D | 1 |
Bjornsti, MA; de Jong, LA; Jansen, LE; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC; Verseyden, C | 1 |
Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW | 1 |
Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E | 1 |
Bandrés, E; Enguita, M; García-Foncillas, J; Garrido, MJ; Moreno, D; Trocóniz, IF | 1 |
Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
Besterman, JM; Brown, HR; Emerson, DL; Evans, MG; Leitner, PP; Luzzio, MJ; Shaffer, JE; Sternbach, DD; Uehling, D; Vuong, A | 1 |
Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A | 1 |
Beijnen, JH; Creemers, GJ; Davies, B; de Boer-Dennert, M; McDonald, M; Rosing, H; Schellens, JH; Verweij, J | 1 |
Willson, JK | 1 |
Berger, NA; Gordon, NH; Mackay, W; Whitacre, CM; Zborowska, E | 1 |
McCann, J | 1 |
Berger, NA; Eshleman, JR; Markowitz, SD; Yang, B | 1 |
Blaese, RM; Morris, JC; Wildner, O | 2 |
Berger, NA; Whitacre, CM; Willson, JK; Zborowska, E | 1 |
Chen, AY; Choy, H; Rothenberg, ML | 1 |
Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
Baguley, BC; Baker, M; Bootle, D; Charlton, PA; Dangerfield, W; Denny, WA; Kofler, B; Mistry, P; Okiji, S; Stewart, AJ | 1 |
Bahadori, HR; Catapano, CV; Green, MR | 1 |
Cheshire, PJ; Houghton, JA; Houghton, PJ; Myers, L; Stewart, CF; Synold, TW | 1 |
2 review(s) available for topotecan and Colonic Neoplasms
Article | Year |
---|---|
Topoisomerase-I inhibitors in the management of colon cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1996 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
3 trial(s) available for topotecan and Colonic Neoplasms
Article | Year |
---|---|
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan | 2006 |
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Carcinoma, Small Cell; Colonic Neoplasms; Cross-Over Studies; Female; Humans; Hydroxy Acids; Lactones; Male; Metabolic Clearance Rate; Middle Aged; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1996 |
36 other study(ies) available for topotecan and Colonic Neoplasms
Article | Year |
---|---|
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1991 |
Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Ovarian Neoplasms; Solubility; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water | 1996 |
Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Drug Design; G2 Phase; HCT116 Cells; Humans; Mice; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators; Xenograft Model Antitumor Assays | 2020 |
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice, Nude; Mitoxantrone; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasm Proteins; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Colonic Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Mice; Mice, Inbred BALB C; Mice, Knockout; Piperazines; Purines; Sildenafil Citrate; Sulfones; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Burden; Vasodilator Agents | 2013 |
Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dendrimers; Drug Carriers; Drug Delivery Systems; HCT116 Cells; Humans; Hyaluronic Acid; Mice; Rats; Sarcoma; Topoisomerase I Inhibitors; Topotecan | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan | 2016 |
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dextrans; Female; Humans; Leukemia, Myeloid; Macrophages; Melanoma; Mice; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays | 2011 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Colonic Neoplasms; Combined Modality Therapy; Crystallography, X-Ray; DNA Damage; Dose-Response Relationship, Drug; Humans; Mice; Mice, Nude; Models, Molecular; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship; Topotecan; Triazoles; Xenograft Model Antitumor Assays | 2012 |
ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Colonic Neoplasms; Diketopiperazines; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; KB Cells; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Rhodamine 123; Topotecan | 2012 |
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease Models, Animal; Female; Fluorouracil; HT29 Cells; Humans; Immunohistochemistry; Injections; Leucovorin; Liver Neoplasms; Mice; Mice, SCID; Organoplatinum Compounds; Survival Rate; Topotecan | 2013 |
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation | 2012 |
The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gene Knockout Techniques; HCT116 Cells; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Multiprotein Complexes; Mutation; Nuclear Proteins; Topotecan; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aberrations; Colonic Neoplasms; Fibroblasts; Glioblastoma; Humans; Lymphocytes; Metaphase; Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topotecan; Tumor Cells, Cultured | 2002 |
Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Topics: Antineoplastic Agents; Colonic Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cisplatin; Colonic Neoplasms; Cytarabine; DNA; DNA Adducts; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Female; Humans; Models, Molecular; Ovarian Neoplasms; Platinum Compounds; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins | 2007 |
Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents.
Topics: Algorithms; Animals; Antineoplastic Agents; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Inhibitory Concentration 50; Rats; Signal Transduction; Time Factors; Topotecan | 2008 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Topics: Animals; Antineoplastic Agents; Body Weight; Camptothecin; Cattle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Thymus Gland; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1993 |
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Induction; Etoposide; Female; Humans; Isoenzymes; Mice; Mice, Nude; Neoplasm Proteins; Topoisomerase II Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 1997 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Death; Colonic Neoplasms; Fluorouracil; Humans; Isopropyl Thiogalactoside; Time Factors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.
Topics: Adenoviridae; Animals; Colonic Neoplasms; Female; Ganciclovir; Genetic Therapy; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Simplexvirus; Thymidine Kinase; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biopsy; Camptothecin; Caspases; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinogenicity Tests; Carcinoma; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Female; Ganciclovir; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Prodrugs; Simplexvirus; Survival Rate; Thymidine Kinase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Topics: Aminoquinolines; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indenes; Inhibitory Concentration 50; Injections, Intraperitoneal; Injections, Intravenous; Isoenzymes; Lung Neoplasms; Mice; Mice, Nude; Phenazines; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Synergistic interaction between topotecan and microtubule-interfering agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; bcl-X Protein; Blotting, Western; Cell Cycle; Colonic Neoplasms; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Enzyme Inhibitors; Formazans; Humans; Microtubules; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tetrazolium Salts; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Vinblastine | 2001 |
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Camptothecin; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Osteosarcoma; Remission Induction; Rhabdomyosarcoma; Time Factors; Topotecan; Tumor Cells, Cultured | 1992 |